Abstract
Results: Compared to primary initiation of a triple therapy, the direct drug cost per SVR would be 12–30% lower when all naive patients would start treatment with Peg/RBV dual therapy initially and switched “on demand” to triple therapy upon not achieving a 1-log10 drop of HCVRNA titer by treatment week 4 or a complete early viral response at treatment week 12 on dual therapy, with the same all over rate of attaining SVR. Conclusions: While Peg/RBV+PI triple therapy is the most effective way to treat any patient with CHC, for naive patients, initiation of dual therapy with Peg/RBV and early identification of those unlikely to achieve an SVR with a full SOC treatment, when followed by an “on demand” switch to triple therapy seems to be a cost-effective approach for healthcare systems with limited financial resources.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
